Search filters

Filters
Clear All

Phase

  • 67
  • 71
  • 1
  • 86
  • 1
  • 60
  • 13
  • 201
  • 576
  • 219
  • 9
  • 25
  • 545
  • 575
  • 4
  • 1
  • 578

Found 579 Barrett's Esophagus trials

A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

18 years - 75 years
All genders
Interventional
The purpose of this research study is to learn more about the safety and performance of SNS when used in patients who have Crohn’s disease or left-sided ulcerative colitis. The InterStim™ Neurostimulator (InterStim) will be used in every participant who agrees to participate and meets all the eligibility criteria for …
18 years - 99 years
Female
Interventional
The purpose of this study is to test a new scanner device that combines two types of imaging called Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DPT) for imaging of a radioactive imaging drug called 18F-Fluoroestradiol (FES), as a diagnostic device for imaging estrogen receptor (ER) positive breast …
18 years - 75 years
All genders
Phase 3
Interventional
This research study is being done to investigate how safe and effective the investigational drug brepocitinib is for treating dermatomyositis. If you agree to join the study, you will be asked to complete the following research procedures: • signing this informed consent • having reviews of your medical/health history and …
18 years - 65 years
All genders
Phase 1
Interventional
This research study is for people who have been waiting for a kidney transplant for at least one year, and who have a cPRA of 99.5% or higher. Having a cPRA of 99.5% or higher means that your immune system would reject 99.5% of kidneys available for transplant. The study …
 NONCOMPACT- International Consortium for Multimodality Phenotyping in Adults with Non-compaction
18 years - 99 years
All genders
This is a prospective, multicenter observational study to identify clinical, genetic and imaging predictors of clinical outcome in patients with suspected non-compaction cardiomyopathy Many healthy people have increased trabeculations without consequences, however, some may develop blood clots, heart rhythm disorders or heart failure later in life. Currently we cannot predict …
18 years - 99 years
All genders
Observational
This study aims to collect and share Parkinson’s disease genetic testing data from up to 500,000 study participants for research use. Participants will include people with Parkinson's disease (PD) and people at-risk for developing PD, and members of the general community that do not have PD. To investigate the genetic …
99 years or below
All genders
Phase 3
The primary safety objective is a composite of the number of Major Adverse Events (MAEs) occurring through 30 days post-procedure compared to the rate in subjects treated with the Relay Thoracic Stent-Graft in the U.S. Pivotal Trial (P110038). The primary effectiveness objective is a composite of the number of effectiveness …
99 years or below
All genders
The basic premise of this pilot study is to enroll 40 patients over 1.5 years who have Stage III or IV non-small cell lung cancer and are planned for definitive treatment with concurrent chemoradiation when a contrast-enhanced 4DCT is planned. The primary goal is to quantify the reproducibility of lung …
 MG0004: A randomized  open-label extension study to investigate the long-term safety  tolerability  and efficacy of rozanolixizumab in adult patients with generalized myasthenia gravis
99 years or below
All genders
Phase 3
Rozanolixizumab is a humanized IgG4 monoclonal antibody that is being developed as an inhibitor of the activity of the neonatal Fc receptor (FcRn) for IgG. By blocking the activity of neonatal FcRn, rozanolixizumab accelerates the catabolism of antibodies and reduces the serum IgG concentration, including pathogenic IgG in MG patients, …
99 years or below
All genders
Phase 2
The purpose of this research study will be to evaluate the safety and effectiveness of two investigational drugs, All-trans retinoic acid (ATRA) and Retifanlimab (anti-PD1 monoclonal antibody), in treating recurrent IDH-mutant gliomas. Objective radiographic response (CR + PR + MR) using Response Assessment in Neuro-Oncology (RANO) criteria by measurable disease …
361 - 370 of 579